COX-2 inhibitors: cancer prevention or cardiovascular risk?

Lancet Oncol. 2005 Feb;6(2):68. doi: 10.1016/s1470-2045(05)01720-1.
No abstract available

Publication types

  • News

MeSH terms

  • Adenoma / drug therapy
  • Cardiovascular Diseases / chemically induced*
  • Celecoxib
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Lactones / adverse effects
  • Lactones / therapeutic use
  • Membrane Proteins
  • Neoplasms / drug therapy*
  • Neoplasms / prevention & control
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Sulfones / adverse effects
  • Sulfones / therapeutic use

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Lactones
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib